TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Cognitive-Motor Interference (CMI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in 24-2 visual field test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Time from removal of Foley catheter until hospital discharge
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: incidence and severity of neuropsychiatric side effects
Endpoint domain: Adverse events/effects
Primary endpoint: Faecal weight and mucus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Opioid prescribing rates
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Chimerism
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inappropriate Disposition
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of Headache Exacerbation with Migraine-Like Features
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of Sleep: Pittsburgh Sleep Quality Index (PSQ-I)
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Headache Area under the Curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of Subjects With Treatment-induced Anti-FSH Antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Drug use
Endpoint domain: Resource use
Primary endpoint: Retention
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Combined endpoint of cardiac death, myocardial infarction, or revascularization
Endpoint domain: Mortality/survival
Primary endpoint: Acne Scarring Improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change from Baseline in the Mean of 5 Time Sit to Stand Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline in the Mean of the Timed Up and Go Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline in the Mean of the 6 Minutes Walking Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PCR corrected cure-rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk of IUD displacement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Daily Pain Numeric Rating Scale (NRS)
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Biodistribution of [68Ga]Pentixafor
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Repeatability of [68Ga]Pentixafor uptake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change in AHI Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Detection of type 2 diabetes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of children with spherical equivalent refraction of at least -0.50D
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Markers of Inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Markers of Renal Injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Hand Grip Force
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Boston naming test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Cerebellar gray matter volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Severe diarrhea
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Drug Liking: Peak Effect (Emax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Drug Liking: Area Under Effect Curve (AUE) From 0-2 Hour
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postinfarct Remodeling
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: SPAQ score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: BOLD signal variation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients with erythrocyte metformin within therapeutic range
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Maximum Plasma Concentration (Cmax) of JNJ-63623872
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Reach the Maximum Plasma Concentration (Tmax) of JNJ-63623872
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration-Time Curve From 0 to Infinite Time (AUC[0-infinity]) Post Dose of JNJ-63623872
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in disease specific knowledge
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change from baseline in information needs
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Needed rescue pain medication post operatively
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: 7 day point prevalence of abstinence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Tracheotomy or permanent assisted ventilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Time to Recurrent Biliary Obstruction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Successful recording of Electrocardiogram (ECG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reflux esophagitis detection rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Adherence to the daily intermittent fasting regimen
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Pain perception intraoperatively
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functional Independence MeasureTM (FIM)/Functional Assessment Measure (FAM) (Total Score)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: PTSD Checklist Military Form (PCL-M) (Total Score)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Beck Depression Inventory Score (Total Score)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Proportion of subjects experiencing gout flare
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinically definite response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in the Modified Rankin Scale (MRS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: At Least 1 Treatment-Related Adverse Event
Endpoint domain: Adverse events/effects
Primary endpoint: recommended Phase 2 dose (RP2D)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: All-cause mortality at 30-day
Endpoint domain: Mortality/survival
Primary endpoint: Maximum tolerated dose (MTD) of quinacrine dihydrochloride
Endpoint domain: Adverse events/effects
Primary endpoint: dosage and time on norepinephrine treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Temporal Summation of Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of Complaints About Device Use and Operation
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of improved clinical outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: frequency and severity of adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Proportions of patients with gastric varices rebleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Memory impairment
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Days admitted to the hospital related to epistaxis
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Percentage of Mothers With HIV-1 RNA Viral Load Less Than 200 Copies/mL at Delivery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Mother-infant Pairs With an Adverse Pregnancy Outcome
Endpoint domain: Adverse events/effects
Primary endpoint: Cumulative Probability of Women Experiencing Grade 3 or Higher Adverse Event
Endpoint domain: Adverse events/effects
Primary endpoint: Cumulative Probability of Infants Experiencing Grade 3 or Higher Adverse Event
Endpoint domain: Adverse events/effects
Primary endpoint: Airway pressure and expiratory flow rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Circulating markers of Nilotinib effect
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Splenic function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Appreciation of one's own appearance
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Concentration of Itraconazole in nasal secretions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: TOCI stage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Attendance at in-person StayQuit sessions
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Attendance at telephone StayQuit sessions
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Zn Absorption
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Exchangeable Zn Pool Size
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Feasibility of emotional processing and interpersonal therapeutic techniques
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Clinical stage according to WB-MRI and CT findings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of adoption of TASSH
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Proportion of participants linked to care and retained in care
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in the level of patient education about disease, drugs and lifestyle modification
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in the number of solved drug-related problems
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Assessment of medications adherence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: PrEP acceptability
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: PrEP knowledge
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Interleukin 22 binding protein expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Prevalence of sodium imbalance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Electrolyte outcomes
Primary endpoint: Severity of traumatic brain injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Pain intensity (within previous 30 days) rating
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Pain intensity (at present time) rating
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in score on each cluster included in the Multi Affect and Pain Survey (MAPS) questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Tissue Stiffness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Who Reported Experiences
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of Participants With Any Fracture
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Volume of sugar-sweetened beverage purchased
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Systemic pro-inflammatory cytokines
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Clearance of Urea
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Clearance of Cystatin C
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Clearance of Beta2-Microglobulin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Clearance of Osteocalcin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: DEXA T-score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Bone health outcomes
Primary endpoint: Number of Participants With Femoral Head Collapse
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in Stroop Interference Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Post-operative complication
Endpoint domain: Adverse events/effects
Primary endpoint: Adherence to Intervention
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Medicine adherence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percentage of families prepared for emergencies
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Type 1 diabetes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Penetration-Aspiration-Score (PAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Cerebrovascular Reactivity at Day 2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Cerebrovascular Reactivity at Day 90
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Infant HIV testing by DNA PCR within 8 weeks after birth
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Risk of grade 2 or higher toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: CPAP mean usage (hours/night)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average number of times participants initiate an interaction with PrEP Smart
Endpoint domain: Life impact
Endpoint subdomain: Other resource use
Primary endpoint: Average number of times subjects respond to a prompt from PrEP Smart
Endpoint domain: Life impact
Endpoint subdomain: Other resource use
Primary endpoint: First occurrence of all-cause mortality
Endpoint domain: Mortality/survival
Primary endpoint: Effective analgesia (NRS score≤ 3)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with an actionable mutation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of hospitalizations and emergency room visits
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Improvement rate of Child-Pugh score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Nitrate Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Serum and Tissue Biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Capillary Perfusion Density
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of Participants Receiving HEC With Complete Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of Participants Receiving MEC With Complete Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: angular displacement of the vertebrae
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Absolute Bioavailability of Oral Balovaptan
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Static and dynamic pain scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of Motor evoked potentials (MEP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change of resting motor threshold (RMT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in LV size
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in LV volume (2D)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in LV systolic function (2D EF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Use of LifeStraw Family
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Blood Glucose in Oral glucose Tolerance Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in ADHD-RS-IV total score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: True positive fraction (TPF) of identified tumour tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: False positive fraction (FPF) of identified tumour tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Frequency of occurrence and severity of abnormal findings in safety investigations
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Heartburn Free 24 Hour Days
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Myocardial Infarction or Stroke
Endpoint domain: Mortality/survival
Primary endpoint: Sensitivity and Specificity of [124I]FIAU
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain experience
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Participants Who Achieve and Maintain the Systolic Blood Pressure Goals
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Participants With Neurological Deteriorations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Total Number of Serious Adverse Events Within the Initial 72 Hours
Endpoint domain: Adverse events/effects
Primary endpoint: Post hospital behavior changes
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Maximum tolerated dose (MTD) or Recommended phase 2 dose (RP2D)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Nitric Oxide Formation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of RA patients prescribed opioids, benzodiazepines, and antidepressants
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in liver and spleen stiffness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tongue features
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants in Clinical Remission at Month 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of cough
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Mean Cumulative Prednisone Dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: standardized uptake values (SUV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: standardized uptake ratios (SUVRs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in delay in skeletal development
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Spatiotemporal distribution of non-pulmonary vein focal impulses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Spatiotemporal distribution of irregular and rotational activation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Frequency of inter-atrial wavefront propagation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Difference of anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Patient Health Questionnaire 9 (PHQ-9)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Generalized Anxiety Disorder - 7
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Difficulties in Emotion Regulation Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Reduction of symptom score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients with pharyngeal mucosa colonization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: trans-meal blood glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number and Severity of Grade 1-2 Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Number and Severity of Grade 3-5 Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With a Best Overall Response (BOR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes